Comparing Solana (NASDAQ:HSDT) and Covalon Technologies (OTCMKTS:CVALF)

Solana (NASDAQ:HSDT) and Covalon Technologies (OTCMKTS:CVALF) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, analyst recommendations, profitability and institutional ownership.

Valuation & Earnings

This table compares Solana and Covalon Technologies”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solana	$6.02 million	19.69	-$40.89 million	($490.68)	0.00
Covalon Technologies	$23.43 million	1.65	$1.47 million	$0.02	70.00

Covalon Technologies has higher revenue and earnings than Solana. Solana is trading at a lower price-to-earnings ratio than Covalon Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Solana and Covalon Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Solana	-679.54%	-104.96%	-20.67%
Covalon Technologies	3.08%	3.31%	2.80%

Institutional & Insider Ownership

18.6% of Solana shares are held by institutional investors. 14.4% of Solana shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for Solana and Covalon Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solana	1	0	1	1	2.67
Covalon Technologies	0	0	0	0	0.00

Solana currently has a consensus target price of $3.50, indicating a potential upside of 62.04%. Given Solana’s stronger consensus rating and higher probable upside, equities analysts plainly believe Solana is more favorable than Covalon Technologies.

Volatility and Risk

Solana has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Comparatively, Covalon Technologies has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500.

Summary

Solana beats Covalon Technologies on 8 of the 15 factors compared between the two stocks.

About Solana

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.

About Covalon Technologies

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company’s platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity. It also offers medical coating platform, a process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device. In addition, the company provides wound care dressings; surgical and peri-operative; and infection management products. It offers its products under the Covalon brand name through third-party distribution networks and company’s direct sales force. The company serves hospitals, wound care centers, burn centers, extended/alternate care and acute care facilities, home health care agencies, and physicians’ offices. Covalon Technologies Ltd. is headquartered in Mississauga, Canada.